<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29617497</article-id><article-id pub-id-type="pmc">5873778</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0114</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>OPCABG for Moderate CIMR in Elderly Patients: a Superior
Option?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Malhotra</surname><given-names>Amber</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>M.Ch</role></contrib><contrib contrib-type="author"><name><surname>Ananthanarayanan</surname><given-names>Chandrasekaran</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>M.Ch</role></contrib><contrib contrib-type="author"><name><surname>Wadhawa</surname><given-names>Vivek</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>M.Ch</role></contrib><contrib contrib-type="author"><name><surname>Siddiqui</surname><given-names>Sumbul</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>M.Ch</role></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Pranav</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>M.Ch</role></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Kartik</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MCh</role></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Komal</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>PhD</role></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Pratik</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MSc</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiovascular and Thoracic Surgery of the U. N.
Mehta Institute of Cardiology and Research Center (affiliated to BJ Medical College,
Ahmedabad), Gujarat, India. </aff><aff id="aff2">
<label>2</label> Department of Research of the U. N. Mehta Institute of Cardiology
and Research Center (affiliated to BJ Medical College, Ahmedabad), Gujarat, India. </aff><author-notes><corresp id="c1">Correspondence Address: Chandrasekaran Ananthanarayanan, Department
of Cardio Vascular and Thoracic Surgery, U. N. Mehta Institute of Cardiology and
Research Center, Civil Hospital Campus, Asarwa, Ahmedabad-380016, Gujarat,
India. Email: <email>drcananthu@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2018</year></pub-date><volume>33</volume><issue>1</issue><fpage>15</fpage><lpage>22</lpage><history><date date-type="received"><day>07</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>21</day><month>7</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To compare the early and late outcomes of off-pump coronary artery bypass
grafting and coronary artery bypass graft + mitral valve repair in elderly
patients with moderate chronic ischemic mitral regurgitation.</p></sec><sec><title>Methods</title><p>One hundred and fifty elderly (age &#x0003e; 70 years) patients with moderate
chronic ischemic mitral regurgitation who underwent off-pump coronary artery
bypass grafting (n=95) or coronary artery bypass graft + mitral valve repair
(n=55) between January 2007 and December 2014 were studied. They were
subdivided according to presence or absence of high operative risk.
Peri-operative variables and early operative outcomes were retrospectively
studied. Survival, mitral regurgitation grade, and functional outcomes were
prospectively analysed.</p></sec><sec><title>Results</title><p>Both groups were comparable in terms of age (<italic>P</italic>=0.23), sex
(<italic>P</italic>=0.74), left ventricle ejection fraction
(<italic>P</italic>=0.6) and preoperative functional class
(<italic>P</italic>=0.52). The mean number of grafts for off-pump
coronary artery bypass grafting group was 3.14 and coronary artery bypass
graft + mitral valve repair was 3.21. Off-pump coronary artery bypass
grafting group had statistically significant better early operative outcomes
<italic>i.e</italic> perioperative blood transfusions, intraaortic
balloon pump usage, arrhythmias, renal dysfunction, liver dysfunction,
sepsis, mean hours of ventilation, intensive care unit stay and operative
mortality. On a prospective follow up of 5&#x000b1;2.33 years (1-9 years),
coronary artery bypass graft + mitral valve repair in low operative risk
subgroup had better improvements in mitral regurgitation grade than off-pump
coronary artery bypass grafting. Both groups had similar improvements in
functional class and cumulative survival was also comparable (63.2%
<italic>vs.</italic> 54.5%).</p></sec><sec><title>Conclusion</title><p>Off-pump coronary artery bypass grafting is a safer alternative to coronary
artery bypass graft + mitral valve repair with better early operative
outcomes and comparable late survival and functional outcomes in elderly
patients with moderate chronic ischemic mitral regurgitation, especially
those with higher operative risk.</p></sec></abstract><kwd-group><kwd>Mitral Valve Insufficiency/surgery</kwd><kwd>Mitral Valve Annuloplasty</kwd><kwd>Mitral Valve/surgery</kwd><kwd>Coronary Artery Bypass</kwd><kwd>Coronary Artery Bypass, Off-Pump</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="80%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= American College of
Cardiology</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= American Heart
Association</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ASE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= American Society of
Echocardiography</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CAD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery
disease</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CIMR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Chronic ischemic mitral
regurgitation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IABP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intra-aortic balloon
pump</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive care unit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricle</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MVRep</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Mitral valve repair</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NYHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= New York Heart
Association</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OPCABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Off-pump coronary artery
bypass grafting</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RIME</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Randomized ischemic
mitral evaluation</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>The number of elderly patients undergoing coronary artery bypass grafting (CABG) is
on the rise. The continuing improvements in myocardial infarction management, timely
thrombolysis and primary percutaneous intervention techniques have saved many lives.
The age of patients presenting for CABG has increased and they have very advanced
disease, both anatomically and functionally. Elderly patients have a higher burden
of surgical risk factors and reduced functional capacity compared to the young. The
prevalence of comorbidities such as cerebrovascular diseases, diabetes mellitus,
chronic obstructive pulmonary disease, renal dysfunction and peripheral arterial
disease are higher in the elderly. Age is a risk factor for poor operative outcome
and elderly patients have worse early evolution in comparison to the
young<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p><p>Optimal management strategy of moderate chronic ischemic mitral regurgitation (CIMR)
has long remained controversial. It is now well understood that CIMR is a bad
prognostic indicator in coronary artery disease (CAD). Mitral regurgitation begets
more mitral regurgitation leading to worsening of mitral regurgitation grade and
early progression to left ventricle (LV) dysfunction. Several studies have shown the
association of CIMR as a negative determinant of survival in patients with
CAD<sup>[<xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r4" ref-type="bibr">4</xref>]</sup>. It is now an accepted
strategy to surgically address severe CIMR and to do revascularization alone for
mild CIMR at the time of myocardial revascularization. Management of moderate CIMR
at the time of CABG is a controversial topic and data regarding the same in elderly
is scanty. The addition of mitral procedure in this subset is a difficult decision
because of added morbidity of cardiopulmonary bypass and cardioplegic arrest for
repair. All the studies on chronic CIMR have compared on-pump CABG and CABG + Mitral
valve repair (MVRep). Off pump coronary artery bypass grafting (OPCABG) has proven
to be a safer alternative to on pump CABG for high risk patients<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> and this has been studied by
many investigators<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>]</sup>. This study aims at
comparing the outcomes of OPCABG and CABG+MVRep in the setting of moderate CIMR in
elderly.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study Design</title><p>Combined retrospective and prospective observational study.</p></sec><sec><title>Inclusion Criteria</title><p>All patients (age &#x0003e; 70 years) who underwent surgery for CAD with moderate CIMR
during the study period (January 2007 to December 2014) were included in the
study.</p></sec><sec><title>Exclusion Criteria</title><p>Patients having any evidence of structural (chordal or leaflet) mitral valve
disease and endocarditis were excluded from the study. Patients who underwent
surgery in extremis or had an emergency surgery were excluded from the
study.</p></sec><sec><title>Study Groups</title><p>Of the 150 patients, 95 (63.33%) underwent OPCABG (group I) and the remaining 55
(36.67%) underwent CABG+MVRep (group II).</p></sec><sec><title>Subgroups</title><p>Both the groups were divided into two subgroups A &#x00026; B according to the
presence or absence of high operative risk, respectively.</p><p>High operative risk is defined as the presence of left ventricular ejection
fraction &#x0003c; 30% and one or more of the following risk factors - preoperative
renal dysfunction, previous stroke and chronic obstructive pulmonary
disease.</p></sec><sec><title>Surgical Procedures</title><p>All patients underwent myocardial revascularization, which included a left
internal mammary artery graft to left anterior descending coronary artery and
great saphenous vein graft for other diseased coronary arteries. Group I
underwent OPCABG &#x00026; group II underwent CABG+MVRep with cardiopulmonary bypass
support. In the patients who underwent MVRep, the mitral valve was inspected to
rule out any structural lesion. MVRep was done using undersized complete
semi-rigid ring (Carpentier-Edwards Physio I annuloplasty ring, Edwards
Lifesciences, Irvine, CA, USA). All patients had a successful repair which was
defined as less than mild mitral regurgitation at the end of the procedure.</p></sec><sec><title>Collection of Data</title><p>All the relevant preoperative, intra-operative and postoperative data were
collected from the respective case files after acquiring permission from the
institute's ethics committee. They were tabulated for comparison of the
subgroups. After acquiring written informed consent, the study cohort was
followed up and their functional class, mitral regurgitation grade and survival
were recorded.</p></sec><sec><title>Definitions</title><p>The definition of moderate ischemic mitral regurgitation followed the guidelines
of the American College of Cardiology (ACC), the American Heart Association
(AHA), and the American Society of Echocardiography (ASE), and was defined as an
effective regurgitant orifice area of 0.20 to 0.39 cm<sup>2</sup>, a regurgitant
volume of 30 to 59 mL per beat, a regurgitant fraction of 30% to 49%, or a vena
contracta width of 0.30 to 0.69 cm<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>
<list list-type="order"><list-item><p>Postoperative renal dysfunction: creatinine &#x0003e; 2mg/dl</p></list-item><list-item><p>Postoperative liver dysfunction: liver enzymes &#x00026; bilirubin &#x0003e;
three times the upper limit of normal value.</p></list-item><list-item><p>Sepsis: presence of positive blood culture with or without fever and
raised white blood cell counts.</p></list-item><list-item><p>Arrhythmia: any supraventricular or ventricular arrhythmia.</p></list-item></list>
</p></sec><sec><title>Statistical Analysis</title><p>The statistical calculations were performed using SPSS software v 20.0 (Chicago,
IL, USA) Quantitative data was expressed as mean &#x000b1; SD whereas qualitative
data was expressed as a percentage. Uni-variate analysis of the continuous data
was performed using Student's t-test for parametric and Mann-Whitney U-test for
non-parametric variables, whereas chi-square test was used for the categorical
data. The cut-off value of <italic>P</italic>&#x0003c;0.05 was considered for the
statistical significance. Survival analysis was performed using Kaplan
Meier.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Baseline Characteristics</title><p>The mean age of the entire cohort was 76.1 years. Demographic and preoperative
clinical characteristics of the study population are presented in <xref ref-type="table" rid="t1">Table 1</xref>. Both groups were comparable in
terms of age (<italic>P</italic>=0.23), sex (<italic>P</italic>=0.74),
haemoglobin (<italic>P</italic>=0.2), extent of CAD (<italic>P</italic>=0.27),
left ventricular ejection fraction (<italic>P</italic>=0.6), comorbidities -
previous stroke (<italic>P</italic>=0.96), diabetes mellitus
(<italic>P</italic>=0.11), hypertension (<italic>P</italic>=0.85), recent
myocardial infarction (<italic>P</italic>=0.19), chronic obstructive pulmonary
disease (<italic>P</italic>=0.69) and renal dysfunction
(<italic>P</italic>=0.09) (<xref ref-type="table" rid="t1">Table 1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Preoperative variables comparison.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="2">Variables</th><th style="border-bottom:hidden" align="center" rowspan="1" colspan="1">OPCABG</th><th style="border-bottom:hidden" align="center" rowspan="1" colspan="1">CABG+MVRep</th><th align="center" rowspan="2" colspan="1"><italic>P</italic> value</th></tr><tr><th align="center" rowspan="1" colspan="1">N=95 (63.33%)</th><th align="center" rowspan="1" colspan="1">N=55 (36.67%)</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">76.32&#x000b1;2.74</td><td align="center" rowspan="1" colspan="1">75.79&#x000b1;2.32</td><td align="center" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" colspan="2" rowspan="1">Sex (male)</td><td align="center" rowspan="1" colspan="1">67 (70.53%)</td><td align="center" rowspan="1" colspan="1">41 (74.55%)</td><td align="center" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" colspan="2" rowspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">36 (37.89%)</td><td align="center" rowspan="1" colspan="1">13 (23.64%)</td><td align="center" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" colspan="2" rowspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">61 (64.21%)</td><td align="center" rowspan="1" colspan="1">37 (67.27%)</td><td align="center" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" colspan="2" rowspan="1">COPD</td><td align="center" rowspan="1" colspan="1">32 (33.68%)</td><td align="center" rowspan="1" colspan="1">16 (29.09%)</td><td align="center" rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" colspan="2" rowspan="1">Recent MI</td><td align="center" rowspan="1" colspan="1">13 (13.68%)</td><td align="center" rowspan="1" colspan="1">13 (23.64%)</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" colspan="2" rowspan="1">Previous stroke</td><td align="center" rowspan="1" colspan="1">4 (4.21%)</td><td align="center" rowspan="1" colspan="1">3 (5.45%)</td><td align="center" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" colspan="2" rowspan="1">SVD</td><td align="center" rowspan="1" colspan="1">27 (28.42%)</td><td align="center" rowspan="1" colspan="1">16 (29.09%)</td><td align="center" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" colspan="2" rowspan="1">DVD</td><td align="center" rowspan="1" colspan="1">32 (33.68%)</td><td align="center" rowspan="1" colspan="1">13 (23.64%)</td><td align="center" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" colspan="2" rowspan="1">TVD</td><td align="center" rowspan="1" colspan="1">19 (20%)</td><td align="center" rowspan="1" colspan="1">19 (34.55%)</td><td align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" colspan="2" rowspan="1">LMCA</td><td align="center" rowspan="1" colspan="1">44 (46.32%)</td><td align="center" rowspan="1" colspan="1">16 (29.09%)</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" colspan="2" rowspan="1">Hb (gm %)</td><td align="center" rowspan="1" colspan="1">11.83&#x000b1;1.64</td><td align="center" rowspan="1" colspan="1">11.5&#x000b1;1.2</td><td align="center" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" colspan="2" rowspan="1">Creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">1.18 &#x000b1;0.59</td><td align="center" rowspan="1" colspan="1">1.24&#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" colspan="2" rowspan="1">Preoperative LVEF (%)</td><td align="center" rowspan="1" colspan="1">35.86&#x000b1;13.25</td><td align="center" rowspan="1" colspan="1">37.06&#x000b1;13.38</td><td align="center" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal dysfunction</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">17 (17.89%)</td><td align="center" rowspan="1" colspan="1">8 (14.55%)</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="4" colspan="1">NYHA</td><td align="left" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">60 (63.16%)</td><td align="center" rowspan="1" colspan="1">31 (56.36%)</td><td align="center" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">35 (36.84%)</td><td align="center" rowspan="1" colspan="1">24 (43.64%)</td><td align="center" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>CABG=Coronary artery bypass grafting; COPD=Chronic obstructive
pulmonary disease; DVD=Double vessel disease; Hb=Hemoglobin;
OPCABG=Off-pump coronary artery bypass grafting. LMCA=Left main
coronary artery; LVEF=Left ventricle ejection fraction;
MI=Myocardial infarction; MVRep=Mitral valve repair; NYHA=New York
Heart Association; SVD=Single vessel disease; TVD=Triple vessel
disease</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Operative Variables</title><p>All patients underwent complete coronary revascularization. The mean number of
grafts in the OPCABG group was 3.14 and in the CABG+MVRep group was 3.21. The
mean cardiopulmonary bypass time and mean aortic cross-clamp time in group II
were 96.67&#x000b1;20.25 and 66.33&#x000b1;13.14 minutes, respectively.</p></sec><sec><title>Early Post-Operative Outcome</title><sec><title>Comparison Between Group I and II</title><p>Irrespective of the operative risk, CABG+MVRep group (II) had higher
incidence of early postoperative complications as compared to OPCABG group
(I) (<xref ref-type="table" rid="t2">Table 2</xref>). The mean number of
blood units transfused [I - 2.2&#x000b1;0.5 <italic>vs.</italic> II -
2.9&#x000b1;1.1 (<italic>P</italic>&#x0003c;0.001)], intra-aortic balloon
pump (IABP) usage [I - 8.42% <italic>vs.</italic> II - 36.36%
(<italic>P</italic>&#x0003c;0.001)], renal dysfunction [I -
8.42 % <italic>vs.</italic> II - 34.55%
(<italic>P</italic>&#x0003c;0.001)], arrhythmias [I - 8.42%
<italic>vs.</italic> II - 27.27% (<italic>P</italic>=0.004)],
liver dysfunction [I - 6.32% <italic>vs.</italic> II - 21.82%
(<italic>P</italic>=0.01)], new onset stroke [I - 5.26%
<italic>vs.</italic> II -23.64% (<italic>P</italic>=0.002)],
sepsis [I - 6.32% <italic>vs.</italic> II - 23.64%
(<italic>P</italic>=0.005)], mean duration of ventilation in
hours [I - 6.92&#x000b1;2.36 <italic>vs.</italic> II -
17.35&#x000b1;4.66 (<italic>P</italic>&#x0003c;0.001)] and intensive care
unit (ICU) stay in days [I - 2.86&#x000b1;1.26 <italic>vs.</italic> II
- 5.87&#x000b1;1.98 (<italic>P</italic>&#x0003c;0.001)], were significantly
more in the CABG+MVRep group. The thirty-day mortality was also high in
CABG+MVRep group [I - 2.11% <italic>vs.</italic> II - 20%
(<italic>P</italic>&#x0003c;0.001)] (<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Early operative outcome comparison between group I and group II.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">OPCABG<break/>N=95 (63.33%)</th><th align="center" rowspan="1" colspan="1">CABG+MVRep<break/>N=55 (36.67%)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Blood transfusion</td><td align="center" rowspan="1" colspan="1">2.2&#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">2.9&#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative IABP</td><td align="center" rowspan="1" colspan="1">8 (8.42%)</td><td align="center" rowspan="1" colspan="1">20 (36.36%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal dysfunction</td><td align="center" rowspan="1" colspan="1">8 (8.42%</td><td align="center" rowspan="1" colspan="1">19 (34.55%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Arrhythmia</td><td align="center" rowspan="1" colspan="1">8 (8.42%)</td><td align="center" rowspan="1" colspan="1">15 (27.27%)</td><td align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver dysfunction</td><td align="center" rowspan="1" colspan="1">6 (6.32%)</td><td align="center" rowspan="1" colspan="1">12 (21.82%)</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">New onset stroke</td><td align="center" rowspan="1" colspan="1">5 (5.26%)</td><td align="center" rowspan="1" colspan="1">13 (23.64%)</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Sepsis</td><td align="center" rowspan="1" colspan="1">6 (6.32%)</td><td align="center" rowspan="1" colspan="1">13 (23.64%)</td><td align="center" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">30-day mortality</td><td align="center" rowspan="1" colspan="1">2 (2.11%)</td><td align="center" rowspan="1" colspan="1">11 (20%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Ventilation (hours)</td><td align="center" rowspan="1" colspan="1">6.92&#x000b1;2.36</td><td align="center" rowspan="1" colspan="1">17.35&#x000b1;4.66</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU stay (days)</td><td align="center" rowspan="1" colspan="1">2.86&#x000b1;1.26</td><td align="center" rowspan="1" colspan="1">5.87&#x000b1;1.98</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>CABG=Coronary artery bypass grafting; IABP=Intra-aortic balloon
pump; ICU=intensive care unit; MVRep=Mitral valve repair;
OPCABG=Off-pump coronary artery bypass grafting</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Subgroup Comparison - High Operative Risk (IA vs. IIA)</title><p>OPCABG patients had better early operative outcomes in comparison with the
CABG+MVRep patients in all the parameters studied (<xref ref-type="table" rid="t3">Table 3</xref>). The mean number of blood units transfused
[IA - 2.3&#x000b1;0.6 <italic>vs.</italic> IIA - 3.1&#x000b1;0.9
(<italic>P</italic>&#x0003c;0.001)], IABP usage [IA - 8.57%
<italic>vs.</italic> IIA - 50% (<italic>P</italic>=0.002)] renal
dysfunction [IA - 11.43% <italic>vs.</italic> IIA - 45%
(<italic>P</italic>=0.01)], arrhythmias [IA - 11.43%
<italic>vs.</italic> IIA - 40% (<italic>P</italic>=0.03)], liver
dysfunction [IA - 8.57% <italic>vs.</italic> IIA - 35%
(<italic>P</italic>=0.04)], new onset stroke [IA - 5.71%
<italic>vs.</italic> IIA - 30% (<italic>P</italic>=0.04)], sepsis
[IA - 8.57% <italic>vs.</italic> IIA &#x000b1; 2.45
<italic>vs.</italic> IIA - 18.24&#x000b1;4.72
(<italic>P</italic>&#x0003c;0.001)] and ICU stay in days [IA -
3.63&#x000b1;1.12 <italic>vs.</italic> IIA - 6.42&#x000b1;2.1
(<italic>P</italic>&#x0003c;0.001)], were significantly more in the
CABG+MVRep group. The thirty-day mortality was also high in CABG+MVRep
subgroup [IA - 2.86% <italic>vs.</italic> IIA - 25%
(<italic>P</italic>=0.04)] (<xref ref-type="table" rid="t3">Table
3</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Early operative outcome comparison in high operative risk subgroup
(A).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">IA - OPCABG<break/>N=35</th><th align="center" rowspan="1" colspan="1">IIA- CABG+MVRep<break/>N=20</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Blood transfusion</td><td align="center" rowspan="1" colspan="1">2.3&#x000b1;0.6</td><td align="center" rowspan="1" colspan="1">3.1&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative IABP</td><td align="center" rowspan="1" colspan="1">3 (8.57%)</td><td align="center" rowspan="1" colspan="1">10 (50%)</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal dysfunction</td><td align="center" rowspan="1" colspan="1">4 (11.43%)</td><td align="center" rowspan="1" colspan="1">9 (45%)</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Arrhythmia</td><td align="center" rowspan="1" colspan="1">4 (11.43%)</td><td align="center" rowspan="1" colspan="1">8 (40%)</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver dysfunction</td><td align="center" rowspan="1" colspan="1">3 (8.57%)</td><td align="center" rowspan="1" colspan="1">7 (35%)</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">New-onset stroke</td><td align="center" rowspan="1" colspan="1">2 (5.71%)</td><td align="center" rowspan="1" colspan="1">6 (30%)</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Sepsis</td><td align="center" rowspan="1" colspan="1">3 (8.57%)</td><td align="center" rowspan="1" colspan="1">7 (35%)</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">30-day mortality</td><td align="center" rowspan="1" colspan="1">1 (2.86)</td><td align="center" rowspan="1" colspan="1">5 (25%)</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Ventilation (hours)</td><td align="center" rowspan="1" colspan="1">7.23&#x000b1;2.45</td><td align="center" rowspan="1" colspan="1">18.24&#x000b1;4.72</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU stay (days)</td><td align="center" rowspan="1" colspan="1">3.63&#x000b1;1.12</td><td align="center" rowspan="1" colspan="1">6.42&#x000b1;2.1</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>CABG=Coronary artery bypass grafting; IABP=Intra-aortic balloon
pump; ICU=Intensive care unit; MVRep=Mitral valve repair;
OPCABG=Off-pump coronary artery bypass grafting</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Subgroup Comparison - Low Operative Risk (IB vs. IIB)</title><p>Even in the low operative risk subgroup, OPCABG patients had significantly
lower incidence of blood units transfused [IB - 2.1&#x000b1;0.5
<italic>vs.</italic> IIB - 2.7&#x000b1;1.5
(<italic>P</italic>=0.005)], IABP usage [IB - 8.33%
<italic>vs.</italic> IIB - 28.57% (<italic>P</italic>=0.02)],
renal dysfunction [IB - 6.67% <italic>vs.</italic> IIB - 28.57%
(<italic>P</italic>=0.001)], mean duration of ventilation in
hours [IB - 6.76&#x000b1;2.25 <italic>vs.</italic> IIB -
15.76&#x000b1;4.13 (<italic>P</italic>&#x0003c;0.001)] and ICU stay in days
[IB - 2.78&#x000b1;1.34 <italic>vs.</italic> IIB - 5.38&#x000b1;1.92
(<italic>P</italic>&#x0003c;0.001)] than the CABG+MVRep patients. The
thirty-day mortality was also low in OPCABG subgroup [IB - 1.67%
<italic>vs.</italic> IIB - 17.14% (<italic>P</italic>=0.01)].
Other parameters were not significantly different between the subgroups
(<xref ref-type="table" rid="t4">Table 4</xref>).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Early operative outcome comparison in low operative risk subgroup
(B).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">IB - OPCABG<break/>N=60</th><th align="center" rowspan="1" colspan="1">IIB- CABG+MVRep<break/>N=35</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Blood transfusion</td><td align="center" rowspan="1" colspan="1">2.1&#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">2.7&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative IABP</td><td align="center" rowspan="1" colspan="1">5 (8.33%)</td><td align="center" rowspan="1" colspan="1">10 (28.57%)</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal dysfunction</td><td align="center" rowspan="1" colspan="1">4 (6.67%)</td><td align="center" rowspan="1" colspan="1">10 (28.57%)</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Arrhythmia</td><td align="center" rowspan="1" colspan="1">4 (6.67%)</td><td align="center" rowspan="1" colspan="1">7 (20%)</td><td align="center" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver dysfunction</td><td align="center" rowspan="1" colspan="1">3 (5%)</td><td align="center" rowspan="1" colspan="1">5 (14.29%)</td><td align="center" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">New-onset stroke</td><td align="center" rowspan="1" colspan="1">3 (5%)</td><td align="center" rowspan="1" colspan="1">7 (20%)</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Sepsis</td><td align="center" rowspan="1" colspan="1">3 (5%)</td><td align="center" rowspan="1" colspan="1">6 (17.14%)</td><td align="center" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">30-day mortality</td><td align="center" rowspan="1" colspan="1">1 (1.67%)</td><td align="center" rowspan="1" colspan="1">6 (17.14%)</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Ventilation (hours)</td><td align="center" rowspan="1" colspan="1">6.76&#x000b1;2.25</td><td align="center" rowspan="1" colspan="1">15.76&#x000b1;4.13</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU stay (days)</td><td align="center" rowspan="1" colspan="1">2.78&#x000b1;1.34</td><td align="center" rowspan="1" colspan="1">5.38&#x000b1;1.92</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>CABG=Coronary artery bypass grafting; IABP=Intra-aortic balloon
pump; ICU=intensive care unit; MVRep=Mitral valve repair;
OPCABG=Off-pump coronary artery bypass grafting</p></fn></table-wrap-foot></table-wrap></sec></sec><sec><title>Follow-Up Study</title><p>In a mean follow-up period of five years, both OPCABG and the CABG+MVRep group
had improvement in the mitral regurgitation grade and New York Heart Association
(NYHA) class.</p></sec><sec><title>Improvement in Mitral Regurgitation Grade</title><p>CABG+MVRep was able to offer better results in terms of mitral regurgitation
reduction in the low operative risk subgroup, however the results are comparable
in the high operative risk subgroup (<xref ref-type="fig" rid="f1">Figure
1</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Follow-up comparison of mitral regurgitation (MR) grade between the
subgroups.</p><p>CABG=coronary artery bypass grafting; MVRep=mitral valve repair;
OPCABG=off-pump coronary artery bypass grafting</p></caption><graphic xlink:href="rbccv-33-01-0015-g01"/></fig>
</p></sec><sec><title>Functional Class Improvement</title><p>In a mean follow up period of five years, both groups had comparable improvements
in their NYHA functional class irrespective of their operative risk. No
statistically significant difference among the subgroups in terms of functional
class improvement was found (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Follow-up comparison of New York Heart Association (NYHA) class
between the subgroups.</p><p>CABG=coronary artery bypass grafting; MVRep=mitral valve repair;
OPCABG=off-pump coronary artery bypass grafting</p></caption><graphic xlink:href="rbccv-33-01-0015-g02"/></fig>
</p></sec><sec><title>Survival</title><p>In a mean follow-up period of five years, 35 patients of the entire cohort (group
I - n=26, group II - n=9) died of non-cardiac cause and 12 (group I - n=7, group
II - n=5) died of cardiac causes. The cumulative survival of OPCABG group was
63.2% and for the CABG + MVRep group was 54.5%. The 5-year survival was similar
in both groups (<xref ref-type="fig" rid="f3">Figure 3</xref>).</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Kaplan-Meier survival curve between the off-pump coronary artery
bypass grafting (OPCABG) and coronary artery bypass grafting (CABG)+
mitral valve repair (MVRep) groups.</p></caption><graphic xlink:href="rbccv-33-01-0015-g03"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This is probably the first study conducted in the elderly to compare the outcome of
OPCABG <italic>versus</italic> CABG+MVRep for moderate CIMR. The routine use of
antiplatelets, statins, beta blockers, and angiotensin converting enzyme inhibitors
has greatly extended the age of CAD patients. It is now a common clinical scenario
to see septuagenarians undergoing surgical myocardial revascularization. Even a
healthy elderly is very different physiologically from a young as they have
age-related thickening and stiffening of blood vessel walls leading to less
elasticity, reduced diastolic function and poor effort tolerance compared to the
young. They have reduced functional reserve of other organ systems compared to the
young<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. The
incidence of cardiovascular disease increases as one's age advances. At 60-79 years,
70% will have cardiovascular disease of some form and 21% will have identifiable
CAD<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.
This is reflected in our study as our cohort also has higher incidence of
comorbidities.</p><p>The morbidity and mortality of surgical myocardial revascularization in the elderly
have reduced significantly. Off-pump technique has added to the safety of surgical
revascularization in the elderly. OPCABG has been shown to have reduced myocardial
injury, reduced renal complications, reduced blood product usage and less
neurological complications than on-pump CABG<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. OPCABG can achieve complete
revascularization comparable to on-pump CABG as shown in this study (mean number of
grafts 3.14 vs. 3.21)<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. In expert hands, OPCABG can also be safely
accomplished in the presence of moderate CIMR.</p><p>CIMR involves incomplete closure of structurally normal mitral valve leaflet and is
due to CAD that affects the LV geometry causing annular dilatation and tenting of
the chordae tendineae<sup>[<xref rid="r13" ref-type="bibr">13</xref>-<xref rid="r15" ref-type="bibr">15</xref>]</sup>. Numerous studies have
indicated association of CIMR with poor survival rates in CAD
patients<sup>[<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Surgical correction of
moderate CIMR at the time of coronary revascularization is still an unresolved
controversy<sup>[<xref rid="r18" ref-type="bibr">18</xref>-<xref rid="r21" ref-type="bibr">21</xref>]</sup>. Even in the recent
ACC/AHA guidelines (2014), the level of evidence for surgical correction of moderate
mitral regurgitation at the time of CABG is class IIB<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>. The addition of MVRep to
CABG requires cardiopulmonary bypass with considerable length of aortic cross clamp
time. Increased incidence of complications can be attributed to cardiopulmonary
bypass in which, tissues and organs may suffer from regional malperfusion. The
elderly with reduced functional reserve of many organ systems are more vulnerable to
the complications of cardiopulmonary bypass. Extracorporeal circulation leads to
various types of cellular injuries<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. There was an increased incidence of
supraventricular arrhythmias in the MVRep group, which may be due to the atrial
incision for left atrial exposure. A similar trend of higher complications (24%)
with CABG+MVRep group was observed by Smith et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>. Randomized Ischemic Mitral Evaluation
(RIME) trial<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>
also reported higher complication rates in MVRep group showing that adding MVRep
should be weighed against the surgical morbidity and mortality risk the patient is
exposed to. In our study, we have noted that CABG+MVRep group had high rate of early
operative complications. We feel that the difference in our study is more pronounced
as OPCABG group is completely excluded from the complications due to cardiopulmonary
bypass.</p><p>We have documented in one of our earlier studies that mitral ring annuloplasty with
CABG in a selected subgroup with severe CIMR provided mid-term improvement in mitral
regurgitation grade and heart failure symptoms and it is a common practice now to
repair severe CIMR at the time of revascularization<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>. There is no consensus
about the benefits of repair in moderate CIMR. Chan et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup> in RIME trial have
reported improved functional capacity and increased LV reverse remodelling with
MVRep and this finding is contradicted by the observations of Smith et
al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup> who,
in their trial had observed similar improvement in functional capacity and
insignificant LV reverse remodelling and increased incidence of untoward events in
the MVRep group. In our study, there was no significant difference in functional
capacity and survival between the groups in a mean follow-up period of five
years.</p><p>On subgroup analysis, we have found that patients with lower operative risk have
better improvement in mitral regurgitation grade from CABG+MVRep as compared to
OPCABG. We propose that they are probably the subgroup of elderly patients who can
be considered for adding MVRep along with revascularization for moderate CIMR, but
at the cost of a higher early postoperative complication rate.</p><p>Majority of the elderly patients have limited physical activity in their routine
lifestyle and their life expectancy is limited. OPCABG can achieve complete
revascularization, is less morbid, and provides comparable benefits in terms of
functional class improvement and survival in the long term in comparison with CABG +
MVRep for elderly patients with moderate CIMR.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>OPCABG is recommended for moderate CIMR in elderly patients with high operative risk.
CABG+MVRep can be considered for moderate CIMR in elderly patients with low
operative risk, but at the cost of higher early operative complications.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AM</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">CA</td><td align="left" rowspan="1" colspan="1">Drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">VW</td><td align="left" rowspan="1" colspan="1">Drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">SS</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">PS</td><td align="left" rowspan="1" colspan="1">Final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">KP</td><td align="left" rowspan="1" colspan="1">Integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">KS</td><td align="left" rowspan="1" colspan="1">Acquisition, analysis, or interpretation of data for
the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">PS</td><td align="left" rowspan="1" colspan="1">Analysis, or interpretation of data for the work; final
approval of the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the U. N. Mehta Institute of Cardiology and
Research Center (affiliated to BJ Medical College, Ahmedabad), Gujarat,
India.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roques</surname><given-names>F</given-names></name><name><surname>Nashef</surname><given-names>SA</given-names></name><name><surname>Michel</surname><given-names>P</given-names></name><name><surname>Gauducheau</surname><given-names>E</given-names></name><name><surname>De Vincentiis</surname><given-names>C</given-names></name><name><surname>Baudet</surname><given-names>E</given-names></name><etal/></person-group><article-title>Risk factors and outcome in European cardiac surgery: analysis of
the EuroSCORE multinational database of 19030 patients</article-title><source>Eur J Cardiothorac Surg</source><year>1999</year><volume>15</volume><issue>6</issue><fpage>816</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">10431864</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamas</surname><given-names>GA</given-names></name><name><surname>Mitchell</surname><given-names>GF</given-names></name><name><surname>Flaker</surname><given-names>GC</given-names></name><name><surname>Smith Jr</surname><given-names>SC</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name><name><surname>Basta</surname><given-names>L</given-names></name><etal/></person-group><article-title>Clinical significance of mitral regurgitation after acute
myocardial infarction. Survival and Ventricular Enlargement
Investigators</article-title><source>Circulation</source><year>1997</year><volume>96</volume><issue>3</issue><fpage>827</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">9264489</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigioni</surname><given-names>F</given-names></name><name><surname>Enriquez-Sarano</surname><given-names>M</given-names></name><name><surname>Zehr</surname><given-names>KJ</given-names></name><name><surname>Bailey</surname><given-names>KR</given-names></name><name><surname>Tajik</surname><given-names>AJ</given-names></name></person-group><article-title>Ischemic mitral regurgitation: long-term outcome and prognostic
implications with quantitative Doppler assessment</article-title><source>Circulation</source><year>2001</year><volume>103</volume><issue>13</issue><fpage>1759</fpage><lpage>1764</lpage><pub-id pub-id-type="pmid">11282907</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hickey</surname><given-names>MS</given-names></name><name><surname>Smith</surname><given-names>LR</given-names></name><name><surname>Muhlbaier</surname><given-names>LH</given-names></name><name><surname>Harrell Jr</surname><given-names>FE</given-names></name><name><surname>Reves</surname><given-names>JG</given-names></name><name><surname>Hinohara</surname><given-names>T</given-names></name><etal/></person-group><article-title>Current prognosis of ischemic mitral regurgitation. Implications
for future management</article-title><source>Circulation</source><year>1988</year><volume>78</volume><issue>3</issue><issue-part>2</issue-part><fpage>I51</fpage><lpage>I59</lpage><pub-id pub-id-type="pmid">2970346</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mack</surname><given-names>MJ</given-names></name><name><surname>Pfister</surname><given-names>A</given-names></name><name><surname>Bachand</surname><given-names>D</given-names></name><name><surname>Emery</surname><given-names>R</given-names></name><name><surname>Magee</surname><given-names>MJ</given-names></name><name><surname>Connolly</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparison of coronary bypass surgery with and without
cardiopulmonary bypass in patients with multivessel disease</article-title><source>J Thorac Cardiovasc Surg</source><year>2004</year><volume>127</volume><issue>1</issue><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">14752427</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffolo</surname><given-names>E</given-names></name><name><surname>Lima</surname><given-names>RC</given-names></name><name><surname>Salerno</surname><given-names>TA</given-names></name></person-group><article-title>Myocardial revascularization without cardiopulmonary bypass:
historical background and thirty-year experience</article-title><source>Rev Bras Cir Cardiovasc</source><year>2011</year><volume>26</volume><issue>3</issue><fpage>III</fpage><lpage>VII</lpage></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerola</surname><given-names>LR</given-names></name><name><surname>Buffolo</surname><given-names>E</given-names></name><name><surname>Jasbik</surname><given-names>W</given-names></name><name><surname>Botelho</surname><given-names>B</given-names></name><name><surname>Bosco</surname><given-names>J</given-names></name><name><surname>Brasil</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Offpump versus on-pump myocardial revascularization in low-risk
patients with one or two vessel disease: perioperative results in a
multicenter randomized controlled trial</article-title><source>Ann Thorac Surg</source><year>2004</year><volume>77</volume><issue>2</issue><fpage>569</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">14759439</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonow</surname><given-names>RO</given-names></name><name><surname>Carabello</surname><given-names>BA</given-names></name><name><surname>Chatterjee</surname><given-names>K</given-names></name><name><surname>Leon Jr</surname><given-names>AC</given-names></name><name><surname>Faxon</surname><given-names>DP</given-names></name><name><surname>Freed</surname><given-names>MD</given-names></name><etal/><collab>American College of Cardiology</collab><collab>American Heart Association Task Force on Practice
Guidelines</collab></person-group><article-title>2008 focused update incorporated into the ACC/AHA 2006 guidelines
for the management of patients with valvular heart disease: a report of the
American College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Writing Committee to revise the 1998 guidelines for the
management of patients with valvular heart disease) Endorsed by the Society
of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography
and Interventions, and Society of Thoracic Surgeons</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><issue>13</issue><fpage>e1</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">18848134</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karavidas</surname><given-names>A</given-names></name><name><surname>Lazaros</surname><given-names>G</given-names></name><name><surname>Tsiachris</surname><given-names>D</given-names></name><name><surname>Pyrgakis</surname><given-names>V</given-names></name></person-group><article-title>Aging and the cardiovascular system</article-title><source>Hellenic J Cardiol</source><year>2010</year><volume>51</volume><issue>5</issue><fpage>421</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">20876055</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Blaha</surname><given-names>MJ</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><etal/><collab>American Heart Association Statistics Committee and Stroke
Statistics Subcommittee</collab></person-group><article-title>Heart disease and stroke statistics-2015 update: a report from
the American Heart Association</article-title><source>Circulation</source><year>2015</year><volume>131</volume><issue>4</issue><fpage>e29</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">25520374</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Ruzzeh</surname><given-names>S</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Yacoub</surname><given-names>M</given-names></name><name><surname>Amrani</surname><given-names>M</given-names></name></person-group><article-title>The clinical outcome of off-pump coronary artery bypass surgery
in the elderly patients</article-title><source>Eur J Cardiothorac Surg</source><year>2001</year><volume>20</volume><issue>6</issue><fpage>1152</fpage><lpage>1156</lpage><pub-id pub-id-type="pmid">11717020</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Ruzzeh</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Athanasiou</surname><given-names>T</given-names></name><name><surname>Modine</surname><given-names>T</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Yacoub</surname><given-names>M</given-names></name><etal/></person-group><article-title>Does off-pump coronary artery bypass (OPCAB) surgery improve the
outcome in high-risk patients?: a comparative study of 1398 highrisk
patients</article-title><source>Eur J Cardiothorac Surg</source><year>2003</year><volume>23</volume><issue>1</issue><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">12493504</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komeda</surname><given-names>M</given-names></name><name><surname>Glasson</surname><given-names>JR</given-names></name><name><surname>Bolger</surname><given-names>AF</given-names></name><name><surname>GT 2nd</surname><given-names>Daughters</given-names></name><name><surname>MacIsaac</surname><given-names>A</given-names></name><name><surname>Oesterle</surname><given-names>SN</given-names></name><etal/></person-group><article-title>Geometric determinants of ischemic mitral
regurgitation</article-title><source>Circulation</source><year>1997</year><volume>96</volume><issue>9</issue><fpage>II128</fpage><lpage>II133</lpage></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>N</given-names></name><name><surname>Ogasawara</surname><given-names>Y</given-names></name><name><surname>Yamaura</surname><given-names>Y</given-names></name><name><surname>Wada</surname><given-names>N</given-names></name><name><surname>Kawamoto</surname><given-names>T</given-names></name><name><surname>Toyota</surname><given-names>E</given-names></name><etal/></person-group><article-title>Mitral annulus flattens in ischemic mitral regurgitation:
geometric differences between inferior and anterior myocardial infarction: a
real-time 3-dimensional echocardiographic study</article-title><source>Circulation</source><year>2005</year><volume>112</volume><issue>9</issue><fpage>I458</fpage><lpage>I462</lpage><pub-id pub-id-type="pmid">16159863</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agricola</surname><given-names>E</given-names></name><name><surname>Oppizzi</surname><given-names>M</given-names></name><name><surname>Maisano</surname><given-names>F</given-names></name><name><surname>De Bonis</surname><given-names>M</given-names></name><name><surname>Schinkel</surname><given-names>AF</given-names></name><name><surname>Torracca</surname><given-names>L</given-names></name><etal/></person-group><article-title>Echocardiographic classification of chronic ischemic mitral
regurgitation caused by restricted motion according to tethering
pattern</article-title><source>Eur J Echocardiogr</source><year>2004</year><volume>5</volume><issue>5</issue><fpage>326</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">15341868</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castleberry</surname><given-names>AW</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name><name><surname>Daneshmand</surname><given-names>MA</given-names></name><name><surname>Honeycutt</surname><given-names>E</given-names></name><name><surname>Shaw</surname><given-names>LK</given-names></name><name><surname>Samad</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Surgical revascularization is associated with maximal survival in
patients with ischemic mitral regurgitation: a 20-year
experience</article-title><source>Circulation</source><year>2014</year><volume>129</volume><issue>24</issue><fpage>2547</fpage><lpage>2556</lpage><pub-id pub-id-type="pmid">24744275</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigioni</surname><given-names>F</given-names></name><name><surname>Detaint</surname><given-names>D</given-names></name><name><surname>Avierinos</surname><given-names>JF</given-names></name><name><surname>Scott</surname><given-names>C</given-names></name><name><surname>Tajik</surname><given-names>J</given-names></name><name><surname>Enriquez-Sarano</surname><given-names>M</given-names></name></person-group><article-title>Contribution of ischemic mitral regurgitation to congestive heart
failure after myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>45</volume><issue>2</issue><fpage>260</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">15653025</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milano</surname><given-names>CA</given-names></name><name><surname>Daneshmand</surname><given-names>MA</given-names></name><name><surname>Rankin</surname><given-names>JS</given-names></name><name><surname>Honeycutt</surname><given-names>E</given-names></name><name><surname>Williams</surname><given-names>ML</given-names></name><name><surname>Swaminathan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Survival prognosis and surgical management of ischemic mitral
regurgitation</article-title><source>Ann Thorac Surg</source><year>2008</year><volume>86</volume><issue>3</issue><fpage>735</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">18721554</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Kang</surname><given-names>SJ</given-names></name><name><surname>Song</surname><given-names>JM</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Mitral valve repair versus revascularization alone in the
treatment of ischemic mitral regurgitation</article-title><source>Circulation</source><year>2006</year><volume>114</volume><issue>1</issue><fpage>I499</fpage><lpage>I503</lpage><pub-id pub-id-type="pmid">16820626</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>DR</given-names></name><name><surname>Agnihotri</surname><given-names>AK</given-names></name><name><surname>Hung</surname><given-names>JW</given-names></name><name><surname>Vlahakes</surname><given-names>GJ</given-names></name><name><surname>Akins</surname><given-names>CW</given-names></name><name><surname>Hilgenberg</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Long-term survival after surgical revascularization for moderate
ischemic mitral regurgitation</article-title><source>Ann Thorac Surg</source><year>2005</year><volume>80</volume><issue>2</issue><fpage>570</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">16039207</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diodato</surname><given-names>MD</given-names></name><name><surname>Moon</surname><given-names>MR</given-names></name><name><surname>Pasque</surname><given-names>MK</given-names></name><name><surname>Barner</surname><given-names>HB</given-names></name><name><surname>Moazami</surname><given-names>N</given-names></name><name><surname>Lawton</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Repair of ischemic mitral regurgitation does not increase
mortality or improve long-term survival in patients undergoing coronary
artery revascularization: a propensity analysis</article-title><source>Ann Thorac Surg</source><year>2004</year><volume>78</volume><issue>3</issue><fpage>794</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">15336993</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>RA</given-names></name><name><surname>Otto</surname><given-names>CM</given-names></name><name><surname>Bonow</surname><given-names>RO</given-names></name><name><surname>Carabello</surname><given-names>BA</given-names></name><name><surname>JP 3rd</surname><given-names>Erwin</given-names></name><name><surname>Guyton</surname><given-names>RA</given-names></name><etal/><collab>American College of Cardiology/American Heart Association Task Force
on Practice Guidelines</collab></person-group><article-title>2014 AHA/ACC guideline for the management of patients with
valvular heart disease: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>63</volume><issue>22</issue><fpage>e57</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">24603191</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>S</given-names></name><name><surname>LeClerc</surname><given-names>JL</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>Inflammatory response to cardiopulmonary bypass: mechanisms
involved and possible therapeutic strategies</article-title><source>Chest</source><year>1997</year><volume>112</volume><issue>3</issue><fpage>676</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">9315800</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>PK</given-names></name><name><surname>Puskas</surname><given-names>JD</given-names></name><name><surname>Ascheim</surname><given-names>DD</given-names></name><name><surname>Voisine</surname><given-names>P</given-names></name><name><surname>Gelijns</surname><given-names>AC</given-names></name><name><surname>Moskowitz</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Surgical treatment of moderate ischemic mitral
regurgitation</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>23</issue><fpage>2178</fpage><lpage>2188</lpage><pub-id pub-id-type="pmid">25405390</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KM</given-names></name><name><surname>Punjabi</surname><given-names>PP</given-names></name><name><surname>Flather</surname><given-names>M</given-names></name><name><surname>Wage</surname><given-names>R</given-names></name><name><surname>Symmonds</surname><given-names>K</given-names></name><name><surname>Roussin</surname><given-names>I</given-names></name><etal/><collab>RIME Investigators</collab></person-group><article-title>Coronary artery bypass surgery with or without mitral valve
annuloplasty in moderate functional ischemic mitral regurgitation: final
results of the Randomized Ischemic Mitral Evaluation (RIME)
trial</article-title><source>Circulation</source><year>2012</year><volume>126</volume><issue>21</issue><fpage>2502</fpage><lpage>2510</lpage><pub-id pub-id-type="pmid">23136163</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Garg</surname><given-names>P</given-names></name><name><surname>Bishnoi</surname><given-names>A</given-names></name><name><surname>Kothari</surname><given-names>J</given-names></name><name><surname>Pujara</surname><given-names>J</given-names></name></person-group><article-title>Ring annuloplasty for ischemic mitral regurgitation: a single
center experience</article-title><source>Asian Cardiovasc Thorac Ann</source><year>2014</year><volume>22</volume><issue>7</issue><fpage>781</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">24887905</pub-id></element-citation></ref></ref-list></back></article>